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INTRODUCTION
Thyroid cancer represents ap-
proximately 0.5–1% of all hu-
man malignancy1. In the UK the 
incidence of thyroid cancer is 2-
3 per 100,000 populations 2. In 
geographical areas of low iodine 
intake and in areas exposed to 
nuclear disasters the incidence of 
thyroid cancer is higher. Benign 
thyroid conditions are much more 
common. In the UK approximately 
8 % of the population have nodular 
thyroid disease2. Nodular thyroid 
disease increases with age and 
is also more common in females 
and in geographical areas of low 
iodine intake. Primary thyroid 
malignancy can be broadly divid-
ed into 2 groups. The ﬁrst group, 
which generally have much bet-
ter prognosis, are the well-differ-
entiated thyroid carcinoma, which 
includes papillary carcinoma, fol-
licular carcinoma and Hürthle 
cell tumours. The second group 
includes the poorly differentiated 
thyroid carcinoma like medullary 
thyroid carcinoma and the ana-
plastic thyroid carcinoma. Other 
rare tumours such as sarcomas, 
lymphomas and the extremely 
rare primary squamous cell car-
cinoma of the thyroid should be 
included in the second group.   
Secondary or metastatic thyroid 
cancer can be from breast, lung, 
colon and kidney malignancies.
AETIOLOGY
There are many factors that are 
implicated in the aetiology of thy-Libyan Journal of Medicine, Volume 1, 2006
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roid cancer these includes:
 
1) Ionising radiation: Exposure 
to ionising radiation is a well-rec-
ognised factor in causing thyroid 
cancer. Following Chernobyl nu-
clear disaster 
in the former 
USSR there 
has been a 
significant 
increase in 
develop-
ment of thy-
roid cancer 
among the 
local popula-
tion including 
children3. 
Nodular thy-
roid disease 
is also found 
to increase 
following  
ionising ra-
diation expo-
sure.
 
2) Genetic predisposition: Med-
ullary thyroid carcinoma can be 
familial and develop on a back-
ground of Multiple Endocrine Ne-
oplasia (MEN) type 2a and type 
2b, which are inherited as Auto-
somal Dominant. MEN type 2a 
includes medullary thyroid carci-
noma, Phaeo-chromocytoma and 
Parathyroid neoplasia. MEN type 
2b includes medullary thyroid car-
cinoma, Phaeochromocytoma, 
Marfanoid appearance with multi-
ple mucosal neuromas of tongue 
and lips and ganglioneuromas of 
the gastrointestinal tract.  
Figure 1:  papillary thyroid carcinoma 
(H&E).
Medullary thyroid carcinoma can 
also be inherited as a familial Non-
MEN medullary thyroid carcinoma 
or can develop sporadically. The 
implicated gene is mutation of the 
RET proto-oncogene.
3) Chronic Lymphocytic Inﬁltra-    www.ljm.org.ly   
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tion: Hashimoto`s 
Autoimmune lym-
phocytic thyroiditis is 
known to predispose 
to development of 
thyroid lymphoma.
 
4) Low iodine in-
take: This is due to 
lower thyroid hor-
mones production 
which consequently 
leads to increase 
production of thyroid 
stimulating hormone 
(TSH) which leads 
to excessive stimu-
lation of the thyroid 
follicles leading to 
development of nodu-
lar thyroid disease and possibly 
promotes cancerous changes in 
follicular cells.
HISTOLOGICAL CLASSIFICA-
TION
 
Primary malignancy of the thy-
roid gland can originate from any 
of the cellular components of the 
gland and is called primary thyroid 
malignancy which can be either 
differentiated or poorly-differen-
tiated. The cellular components 
of the thyroid glands are follicu-
lar cells and para-follicular cells, 
lymphoid cells and stromal cells.
Figure 2:  follicular cell carcinoma 
(H&E).
Tumours originating from thy-
roid follicles are called follicular 
cell-derived thyroid carcinoma 
(FCDC) (Figures 1, 2 and 3). 
FCDC represent the majority of 
thyroid carcinoma (80–90%)4 
and includes papillary thyroid car-
cinoma, follicular carcinoma and 
Hürthle cell carcinoma. The his-
tological appearance of papillary 
carcinoma is complex, branching 
papillae with ﬁbrovascular cores. 
Nuclei are overlapping with ﬁnely 
dispersed optically clear chroma-
tin (ground-glass appearance). Libyan Journal of Medicine, Volume 1, 2006
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Psammoma bodies that represent 
necrosis of tumor cells with calci-
ﬁcation can be seen in between 
tumor cells, and are fairly speciﬁc 
for papillary carcinoma. 
In follicular carcinoma there is in-
vasion of adjacent thyroid paren-
chyma, blood vessels or capsule 
with usually uniform cells with ab-
sence of nuclear features of pap-
illary carcinoma.
Figure 3: Hürthle cell carcinoma 
(H&E).
 
Hürthle cell carcinoma is a very 
rare differentiated thyroid tumour. 
Hürthle cells are part of follicu-
lar cells. The German histologist 
“Hürthle” ﬁrst described them. 
Their rule in the thyroid follicle is 
still not very clear. They are large, 
polygonal cells characterized by 
extensive mitochondrial content 
which gives it its characteristic 
granular, eosinophilic cytoplasm, 
hence the other name eosi-
nophilic cell. Hürthle cell tumour 
can be either benign or malig-
nant. Histological 
demonstration 
of capsular and 
vascular invasion 
is important in di-
agnosing malig-
nancy.
Para follicular C 
cells gives rise to 
medullary thyroid 
carcinoma and 
constitute 5–10% 
of total thyroid 
cancer.
 
Other primary 
thyroid carci-
nomas that are 
much less com-
mon include ma-
lignant lymphomas, sarcomas, 
anaplastic carcinomas, and the 
very rare squamous cell carcino-
mas. Secondary thyroid cancer     www.ljm.org.ly   
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are usually due to direct spread 
from adjacent structures like for 
example cancers of the larynx or 
hypoharynx or can be due to hae-
matogenous spread from cancer 
of the breast, colon, kidney and 
lungs. 
Figure 4: FNAC of papillary cell carci-
noma (H&E).
CLINICAL PRESENTATION
 
1) Solitary thyroid nodule or dom-
inant nodule in a multinodular 
goitre: This is the most common 
way of presentation of thyroid 
cancer. A solitary thyroid nodule 
carries a risk of 10–20% of being 
malignant2. The risk is higher in 
the very young and the elderly 
and those who had previous ex-
posure to ionising radiation.
 
2) Pressure symptoms: Com-
pression to nearby structure like 
the oesophagus and trachea will 
lead to gradual and progressive 
dysphagia to solid food and/or 
shortness of breath 
on exertion due to 
limitation of airﬂow. 
Severe airway ob-
struction can lead 
to stridor, which 
can also be a re-
sult of vocal cords 
paralysis due to di-
rect tumour inﬁltra-
tion.
 
3) Change in voice 
quality, Dyspho-
nia: This is usually 
due to vocal cords 
paralysis, which 
causes hoarseness of voice.
 
4) Regional or distant metastasis: 
Cervical neck swelling due to me-
tastasis at regional lymph nodes 
in the neck can be the only pre-
senting symptom of thyroid ma-
lignancy in about 20% of patients. 
Distant metastasis to the lungs or 
bones can also be the presenting 
symptom in follicular thyroid car-
cinoma.
 
5) Hormonal Changes: Thyrotoxi-Libyan Journal of Medicine, Volume 1, 2006
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cosis due to toxic thyroid carcino-
ma is extremely rare.
 
INVESTIGATION
1) FNAC (Fine Needle Aspiration 
Cytology): Fine needle aspiration 
cytology is the single most impor-
tant investigation to carry out in 
patients with a thyroid nodule5. It 
has the ability to give a diagno-
sis in about 85% of patients and 
differentiate benign thyroid condi-
tions from neoplastic thyroid con-
ditions, provided a representative 
cellular tissues are obtained and 
examined by an expert cytologist; 
where features of cellular neopla-
sia are recognised like cellular 
and nuclear atypia, enlarged nu-
clei, increase mitosis and hyper-
chromatism. An example of FNAC 
in papillary thyroid carcinoma is 
shown in ﬁgure 4. FNAC has its 
limitation in follicular thyroid can-
cer, as it cannot differentiate be-
tween follicular adenoma and fol-
licular carcinoma, and the report 
is usually read as indeterminate 
follicular neoplasm. Vascular and 
capsular invasion needs to be 
demonstrated histologically in 
order to diagnose follicular car-
cinoma; and for this reason core 
biopsy or more commonly thyroid 
lobectomy is required when fac-
ing this situation to obtain histo-
logical diagnosis. If the results of 
the FNAC are inconclusive which 
is usually due to insufﬁcient ma-
terial aspirated, the procedure 
can simply be repeated to obtain 
enough sample materials. 
 
2) Thyroid Ultrasound: Thyroid 
ultrasound can be helpful in dif-
ferentiating solitary nodules from 
multinodularity seen in benign 
nodular thyroid disease, or can be 
used in guiding FNAC (Ultrasound 
guided FNAC). It is very impor-
tant to realise that thyroid carci-
noma especially follicular thyroid 
cancer can arise as a dominant 
nodule in multinodular goitre and 
a FNAC of the dominant nodule 
should be attempted.
 
3) Radioisotope thyroid scan: The 
radioisotope thyroid scan is usu-
ally used to investigate a patient 
with solitary thyroid nodule to 
measure its activity. The isotope 
used for diagnostic scanning is 
usually Technetium pertecnetate 
(Tc 99m) or radioactive iodine 
(123I or 131I). It is also useful in 
multinodular goitre to detect the 
presence of autonomous func-
tioning nodules.  A metabolically 
very active nodule (hot nodule) 
has an extremely low risk of be-
ing malignant. A metabolically in-
active nodule (cold nodule) has 
a risk of about 10–20% of being     www.ljm.org.ly   
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malignant and this risk also de-
pends on other factors like age, 
gender and previous exposure 
to ionising radiation. The risk is 
higher for the very young and the 
elderly and for males and those 
with previous history of radiation 
exposure.
 
4) Other Imaging studies: Chest 
X-ray can be useful in detecting 
pulmonary metastasis in follicular 
carcinoma. Both computerized to-
mography (CT) and magnetic res-
onance imaging (MRI) can have 
a very important rule in assessing 
the extent of tumour spread and 
involvement of the local struc-
tures around the thyroid like the 
larynx, pharynx and the oesopha-
gus. This will help in planning the 
surgical approach and the degree 
of surgical resection required es-
pecially in large and extensive 
thyroid tumours with extra thyroid 
extension that are involving the 
nearby important structures.
 
5) Laboratory investigations: Thy-
roid function test (TFT) and base-
line thyroglobulin level can be 
useful in both monitoring the dis-
ease progression after treatment 
and to detect early recurrences. 
TFT should be performed regu-
larly to ensure a low level of thy-
roid stimulating hormone (TSH) is 
achieved when adjuvant therapy 
with thyroxin is given in treating 
thyroid cancer. The presence of 
thyroglobulin in the blood is in-
dicative of thyroid tissue activity 
in the body. Its level is used as a 
tumour marker and a monitoring 
tool to detect any active residual 
thyroid tissue in the body, which 
may require further ablation ther-
apy with radioactive iodine; this 
will be discussed later. Serum 
calcitonin measurement is useful 
in case of medullary carcinoma 
thyroid because cancer cells se-
crete it so it can be used both for 
diagnosis and disease monitor-
ing.   
 
PROGNOSIS AND STAGING OF 
THYROID CANCER
 
Several factors have been found 
which stratify the risk of mortal-
ity and aggressiveness of a dif-
ferentiated thyroid cancer. These 
factors are used in planning the 
suitable treatment option in each 
patient, and the aim is to cure 
the patient with the least morbid-
ity, and will help the clinicians to 
identify those high risk patients 
who need more aggressive treat-
ment and adjuvant therapy and 
more stringent follow up. Twenty 
years survival rate for differentiat-
ed thyroid cancer is around 90% Libyan Journal of Medicine, Volume 1, 2006
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because most of these are papil-
lary, which generally have excel-
lent prognosis5.
 
The “Tumour–Node–Metastasis” 
system (TNM) is an internation-
ally accepted system for tumour 
staging and is used in staging of 
thyroid cancer. TNM system was 
developed by the International 
Union Against Cancer (UICC) 
and the American Joint Commis-
sion on Cancer (AJCC). Age of 
the patient is included in the TNM 
staging of thyroid cancer, which is 
unique. Patients who are aged 45 
or older do worse than those who 
are younger and should be treat-
ed more aggressively. The TNM 
staging system is demonstrated 
in table (1).
 
There are also other staging or 
scoring systems that have been 
developed to allow a means of 
predicting tumour behaviour, risk 
of recurrence and survival rate. 
 
AGES scoring system was de-
veloped by Hay et al in 1987 and 
uses age (whether younger or 
older than 40 years), grade of tu-
mour, extent of tumour (extra thy-
roid extension or distant metasta-
sis), and size of primary tumour. 
Low risk scores are those who 
scores 3.99 or less6, 7.
 
Cady and Rossi developed the 
AMES scoring system in 1988, 
which is based on age, metasta-
sis (if present), extent of primary 
tumour (intra thyroidal versus ex-
tra thyroidal), and size of primary 
tumour). The score results will 
stratify the patients into either low 
or high-risk group8.
Other systems include MACIS, 
which describes metastasis, age, 
completeness of primary surgical 
resection, invasion (presence of 
extra thyroidal invasion) and the 
size of primary tumour.  
 
GASH scoring system has also 
been developed which includes 
gender in the risk estimation as 
males are known to do worse than 
females in thyroid cancer treat-
ment and should be regarded as 
a higher risk than female counter-
part. The factors used in GASH 
are gender, age, stage and histol-
ogy2.
TREATMENT OF THYROID 
CANCER
 
Treatment of Thyroid Cancer 
should be by multimodality treat-
ment through multidisciplinary 
team approach; involving a sur-
geon, an endocrinologist, a ra-    www.ljm.org.ly   
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diotherapist and an oncologist. 
Selection of the appropriate treat-
ment depends on the type of risk 
and the characteristics encoun-
tered for both the tumour as well 
as the patient.
 
1) Papillary Carcinoma Thyroid: 
Papillary thyroid carcinoma is 
the most common differentiated 
thyroid cancer and constitutes 
about 80% of all differentiated 
thyroid cancer. Ten-year survival 
is around 98%. The treatment 
for low risk patients with papil-
lary carcinoma like for example 
females less than 45 years old 
with tumour limited to the thyroid 
gland can be adequate with thy-
roid lobectomy followed by TSH 
suppressive therapy in the form 
of Thyroxin supplements and life 
long monitoring using thyroglobu-
lin level with regular clinical eval-Libyan Journal of Medicine, Volume 1, 2006
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uation9. The argument against 
this approach is the possibility 
of dealing with multifocal papil-
lary thyroid carcinoma in small 
percentage of patients. High risk 
patients like males and those 
older than 45 years old with high 
grade tumours should undergo 
total thyroidectomy followed by 
radioactive iodine (131I) ablation 
of thyroid remnants and any pos-
sible residual thyroid tumour us-
ing radioactive Iodine (131I). This 
is followed by TSH suppressive 
therapy to prevent tumour stimu-
lation by TSH, which is achieved 
by giving the patient thyroxin 
supplement in TSH suppressive 
dose.
Follow up for life is also required 
with Thyroglobulin level and 
regular isotope scans. Thyroxin 
should be stopped 4 weeks prior 
to performing 13 1I radioisotope 
follow-up scanning, to facilitate 
rise in TSH to improve 13 1I up-
take by any residual tumour or 
thyroid tissues. Any residual tu-
mour or thyroid tissue detected 
should be dealt with by ablative 
radioactive 131I dose.   Regional 
lymph nodes involvement should 
be surgically dealt with at the time 
of the primary surgery by selec-
tive or modiﬁed radical neck dis-
section depending on the severity 
of lymph node involvement. Un-
like in cervical lymphadenopathy 
squamous cell carcinoma sec-
ondaries from head and neck pri-
mary sites, regional lymph nodes 
involvement in differentiated thy-
roid carcinoma does not greatly 
affect the overall survival. 
 
A more radical surgery to the lar-
ynx, pharynx and the oesopha-
gus is sometimes required to 
eradicate the disease when these 
structures are involved through 
direct tumour spread. This can 
range from tumour shaving of the 
thyroid cartilage, cricotracheal re-
section to partial or total pharyn-
golaryngectomy. The decision of 
the type of resection will depend 
on the part of the airway that is in-
volved by the tumour and the re-
sidual tumour-free airway frame-
work. External beam radiation 
can also be required for tumours 
that do not adequately take up ra-
dioactive iodine.
 
2) Follicular Carcinoma: Follicular 
carcinoma thyroid is more aggres-
sive than papillary carcinoma but 
less aggressive than medullary 
thyroid carcinoma. It is less com-
mon than papillary thyroid carci-
noma and constitutes around 15–
20% of total thyroid carcinoma10.   
It is a differentiated tumour aris-    www.ljm.org.ly   
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ing from thyroid follicles so the 
majority takes up radioactive io-
dine. The planning of treatment 
also depends on the degree of 
risk with lower threshold for total 
thyroidectomy than in papillary 
thyroid carcinoma. Radioactive 
iodine for thyroid ablation of any 
residual thyroid or tumour tissue 
should be done and a follow up 
for life with clinical, radioisotope 
scanning and thyroglobulin level 
monitoring should also be done.  
 
3) Hürthle cell carcinoma: Hürthle 
cell carcinoma is now regarded 
by the WHO as a variant of fol-
licular carcinoma. Although con-
troversial, it is still generally rec-
ognised as an aggressive form of 
differentiated thyroid cancer. The 
treatment protocol will be simi-
lar to that for follicular cell car-
cinoma. Hürthle cell carcinoma 
may not concentrate radioactive 
iodine as well as other differenti-
ated thyroid cancer; nontheless, 
radioactive iodine ablation of any 
remnant thyroid tissues should 
be done to allow for thyroglobulin 
level monitoring.
 
4) Medullary Thyroid Carcinoma:   
urgery in the form of total thyroid-
ectomy and neck dissection for 
nodal involvement gives the best 
chance of cure. As these tumours 
originally arise from Para follicu-
lar C cells (calcitonin producing 
cells), so it is not a surprise that 
they do not concentrate radioac-
tive iodine and so external beam 
radiotherapy can be offered as 
adjuvant treatment for more ex-
tensive disease involvement. 
Follow-up for life by regular clini-
cal examination and monitoring 
of calcitonin level in the blood 
should be done. First-degree rel-
atives should be screened for fa-
milial type of disease using calci-
tonin level or more accurately by 
detecting a mutated proto-onco-
gene. Family members who car-
ry the mutated proto-oncogene 
should undergo elective thyroid-
ectomy to avoid the inevitable 
chance of developing medullary 
thyroid cancer. These patients 
should also be screened for MEN   
type 2 prior to any surgical proce-
dure where phaeochromocytoma 
and parathyroid hyperplasia can 
be associated. It is important to 
remember that medullary thyroid 
cancer can be sporadic (non fa-
milial). A familial non-MEN medul-
lary thyroid carcinoma does also 
exist and it is also important to be 
remembered.
 
5) Anaplastic Thyroid Carcinoma: 
This is a very aggressive malig-
nant tumour of the thyroid, which 
usually presents in the elderly Libyan Journal of Medicine, Volume 1, 2006
page
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with a very rapidly growing hard 
goitre that can compress the air-
ways leading to stridor. It car-
ries a very poor prognosis and 
all these tumours are considered 
T4. It is very important to obtain 
tissue for histological diagnosis 
as malignant lymphoma, which 
has a better prognosis, can have 
a similar presentation. The treat-
ment is usually palliative with ra-
diotherapy. Tracheostomy is often 
required to maintain the airway 
patency.        
 
6) Malignant Lymphoma: Lym-
phoma is treated as for any other 
lymphoma in the body. A histolog-
ical typing and grading along with 
staging CT scan and a referral to 
a medical oncologist is required. 
 
7) Other Rare Thyroid Tumours: 
Soft tissue sarcomas and squa-
mous cell carcinoma of the thy-
roid are very rare and are beyond 
the scope of this review. 
 
CONCLUSION 
 
Multidisplinary team approach 
along with departmental Auditing 
and Quality Assurance should 
offer the best quality of care to 
thyroid cancer patients. These 
patients are generally requires 
lifelong medical care and follow-
up.  
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